Drug
Entacapone clinical trials
Also written Comtan and Comtess.
- studies test it
- 22
- open now
- 2
- in phase 3
- 3
- first study started
- 1997
Keep track of what changes. Save the entacapone studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Combined with it in one product
- CLE
- 1
Studies by the year they started
22 studies that test it; most in 2005 (3)
| Year | Studies |
|---|---|
| 1997 | 1 |
| 2002 | 1 |
| 2003 | 2 |
| 2004 | 2 |
| 2005 | 3 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 3 |
| 2010 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2020 | 1 |
| 2023 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 6
- Phase 2
- 6
- Phase 3
- 3
- Phase 4
- 8
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 11
Novartis (5) · Novartis Pharmaceuticals (3) · Orion Corporation, Orion Pharma (2) · Satish R. Raj (1) · Xiangya Hospital of Central South University (1) · Impax Laboratories, LLC (1) · Oregon Health and Science University (1) · New York State Psychiatric Institute (1)
Often tested with
Tested in the same studies.
Carbidopa (14) · Levodopa (13) · Carbidopa, levodopa drug combination (2) · Acetazolamide (1) · Atomoxetine (1) · Clonidine (1) · Propranolol (1) · Indomethacin (1)
Studies
Open first, then newest update. How each study uses entacapone is read from its arms, and is right about nine times in ten.
Testing it · 22
- Entacapone Plus Bevacizumab for Glioblastoma at First RecurrenceNot yet recruitingPhase 1/2First Affiliated Hospital of Wenzhou Medical UniversityNCT07831187Written as Entacapone
- Basic and Clinical Studies of Levodopa/Carbidopa/Entacapone in the Treatment of Early Parkinson's DiseaseRecruitingPhase 4Second Affiliated Hospital of Soochow UniversityNCT06236230Written as levodopa/carbidopa/entacapone
- Treatment of Orthostatic IntoleranceActive, not recruitingPhase 1/2Satish R. RajNCT00262470Written as Entacapone
- An Extension Study of Entacapone in Patients With Parkinson's Disease With End-of-dose Wearing-off. This Study is Not Recruiting in the United StatesCompletedPhase 2NovartisNCT00237263Written as Entacapone
- Entacapone Combination With Imatinib for Treatment of GISTCompletedEarly Phase 1Xiangya Hospital of Central South UniversityNCT04006769Written as Entacapone
- A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066CompletedPhase 3Impax Laboratories, LLCNCT01130493Written as CLE
- Pilot Study of Entacapone for Methamphetamine AbuseCompletedEarly Phase 1Oregon Health and Science UniversityNCT02058966Written as Entacapone
- Behavioral and Physiological Effects of Cocaine in Cocaine-dependent Participants Treated With Levodopa in Combination With Carbidopa and Entacapone (LCE)CompletedPhase 1New York State Psychiatric InstituteNCT01437293Written as L-dopa / carbidopa / entacapone (LCE)
- A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/LevodopaCompletedPhase 3NovartisNCT00134966Written as capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)
- Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's DiseaseCompletedPhase 4Novartis PharmaceuticalsNCT00219284Written as Carbidopa/levodopa/entacapone
- Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United StatesCompletedPhase 4NovartisNCT00143026Written as carbidopa, levodopa, entacapone
- Effect of Entacapone on Bodyweight Loss in Obese PopulationStatus unknownPhase 1/2Kaichun WuNCT02349243Written as Entacapone
- Augmenting Effects of L-DOPS With Carbidopa and EntacaponeTerminatedPhase 1/2National Institute of Neurological Disorders and Stroke (NINDS)NCT00547911Written as Entacapone
- Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing OffWithdrawnPhase 4Novartis PharmaceuticalsNCT00601978Written as Carbidopa/Levodopa/Entacapone
- Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa TherapyCompletedPhase 3Novartis PharmaceuticalsNCT00099268Written as Carbidopa/levodopa/entacapone
- Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Early Wearing-offCompletedPhase 4NovartisNCT00391898Written as Levodopa/carbidopa/entacapone
- Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing OffTerminatedPhase 4NovartisNCT00642356Written as Carbidopa/levodopa/entacapone
- Entacapone Augmentation for SchizophreniaCompletedNot applicableRambam Health Care CampusNCT00192855Written as Entacapone
- Pharmacokinetics of Levodopa/Carbidopa Infusion With and Without Oral Catechol-O-methyl Transferase (COMT) InhibitorsCompletedPhase 4Uppsala UniversityNCT00906828Written as entacapone
- Pharmacokinetic Study With Repeated Doses of StalevoCompletedPhase 1Orion Corporation, Orion PharmaNCT00693862Written as levodopa, carbidopa, entacapone
See all 22 studies that test entacapone →
Given in every arm · 8 — entacapone is usual care beside what is tested
- [18F]F-DOPA Imaging in Patients With Autonomic FailureRecruitingPhase 1Daniel ClaassenNCT04246437Written as Entacapone 400mg oral dose
- A Safety, Tolerability and Levodopa Pharmacokinetics Study of Repeated ND0612 in Parkinson's Disease PatientsCompletedPhase 2NeuroDerm Ltd.NCT01883505Written as Entacapone
- A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease PatientsCompletedPhase 1NeuroDerm Ltd.NCT02096601Written as Entacapone
- Effect of BIA 6-512 at Steady-state on the Levodopa PharmacokineticsCompletedPhase 1Bial - Portela C S.A.NCT03094156Written as Comtan®
- Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa PharmacokineticsCompletedPhase 1Bial - Portela C S.A.NCT03091868Written as Comtan®
- The Effect of BIA 9-1067 at Steady-state on the Levodopa PharmacokineticsCompletedPhase 1Bial - Portela C S.A.NCT02170376Written as Entacapone
- Study of BIA 9-1067 to Investigate Its Effect on Levodopa PharmacokineticCompletedPhase 1Bial - Portela C S.A.NCT01519284Written as Entacapone
- PET-Study: Effects of Single Doses of Stalevo and Levodopa/Carbidopa on Striatal 11C-Raclopride BindingTerminatedPhase 2Orion Corporation, Orion PharmaNCT00562198Written as entacapone and carbidopa
As the comparator · 8 — what is tested is compared with entacapone
- Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With "Wearingoff" PhenomenonCompletedPhase 2Bial - Portela C S.A.NCT03103399Written as Comtan®
- Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease PatientsCompletedPhase 2Bial - Portela C S.A.NCT02834507Written as Comtan®
- Pharmacokinetic Study in Healthy VolunteersCompletedPhase 1Orion Corporation, Orion PharmaNCT02554734Written as levodopa, carbidopa, entacapone
- Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" PhenomenonCompletedPhase 3Bial - Portela C S.A.NCT01568073Written as Entacapone
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-104 in Healthy VolunteersCompletedPhase 1Orion Corporation, Orion PharmaNCT01840423Written as Entacapone
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-103 in Healthy VolunteersCompletedPhase 1Orion Corporation, Orion PharmaNCT01688089Written as Entacapone
- PK, PD and Safety of Multiple Doses of V1512 Tablets in PD Patients Compared to Standard Levodopa/Carbidopa Oral TabletsCompletedPhase 1/2Vernalis (R&D) LtdNCT00491998Written as V1512 and Entacapone
- COMT Polymorphism and Entacapone EfficacyCompletedPhase 4Assistance Publique - Hôpitaux de ParisNCT00373087Written as entacapone
Codes
What other systems call entacapone · ClinicalTrials.gg INT003592
- MeSH (NLM) C071192entacaponeConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 4975G9NM6TENTACAPONEConfirmed FDA, NLM, Wikidata
- RxNorm 60307Confirmed FDA, Wikidata
- Wikidata Q416444entacaponeConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C61746EntacaponeOne source FDA
- DrugBank DB00494One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C071192 | entacapone | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 4975G9NM6T | ENTACAPONE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 60307 | — | Confirmed FDA, Wikidata |
| Wikidata | Q416444 | entacapone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C61746 | Entacapone | One source FDA |
| DrugBank | DB00494 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.